Collegium Pharmaceutical Inc - Company Profile
Powered by
All the data and insights you need on Collegium Pharmaceutical Inc in one report.
- Save hours of research time and resources with
our up-to-date Collegium Pharmaceutical Inc Strategy Report
- Understand Collegium Pharmaceutical Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that develops and commercializes next generation extended-release, abuse-deterrent products for the treatment of chronic pain and acute pain. R&D focus, lead product Xtampza ER, and DETERx technology platform are its strengths even as customer concentration could be a major cause for concern for the company. The company could benefit from market opportunity of Xtampza ER, increased growth potential for pain medications, and strategic acquisitions. However, high competition, dependence on third party suppliers, and stringent regulations could affect the company's growth prospects.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer